Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Willy Woo: Few Publicly Investable Assets Can Match Bitcoin's Long-term Performance

Willy Woo: Few Publicly Investable Assets Can Match Bitcoin's Long-term Performance

Bitget2025/05/18 21:48
Show original

Cryptocurrency analyst Willy Woo stated on the X platform, "Bitcoin has long passed the stage of several-fold annual growth as seen in 2017. In 2020, Bitcoin began to institutionalize, with corporations and sovereign nations increasing their holdings, and the compound annual growth rate dropped from over 100% to 30-40%. As the network continues to store more capital, the annual compound growth rate shows a declining trend. Bitcoin is now traded as the latest macro asset in 150 years, and it will continue to absorb global capital until it reaches some 'equilibrium point.' Considering the long-term monetary expansion is about 5% and GDP growth is 3%, I believe Bitcoin's eventual compound annual growth rate will stabilize at around 8%. It may take another 15 to 20 years to reach the 'equilibrium point.' There are almost no other publicly investable assets that can match Bitcoin's long-term performance.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks